Contract Pharmaceutical Research Services in the US: Market Size, Businesses & Forecast 2026

The contract pharmaceutical research services industry in the US involves specialized firms providing research, development, and testing services to pharmaceutical and biotechnology companies. The industry has experienced steady growth, with the US pharmaceutical research and development services sector generating approximately $130.5 billion in output in 2022 (BEA). This growth trajectory reflects increasing outsourcing of drug development processes by pharmaceutical companies seeking specialized expertise and cost efficiency.

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Contract Pharmaceutical Research Services in the US industry cover?

Contract pharmaceutical research services encompass a range of specialized scientific activities including preclinical research, clinical trial management, analytical testing, and regulatory support. These services enable pharmaceutical companies to access specialized expertise and infrastructure without maintaining in-house capabilities for every aspect of drug development.

• •The industry includes Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and specialized laboratories providing analytical and formulation services (FDA, 2023)
• •Services span drug discovery, preclinical studies, clinical trial management, and post-marketing surveillance services (NIH, 2023)

Who operates in the industry and how is it structured?

The industry features a mix of large multinational firms with comprehensive service offerings and smaller specialized providers focusing on niche areas. Market players serve pharmaceutical and biotechnology companies of various sizes, from large multinational corporations to emerging biotech startups.

• •Large CROs like IQVIA, Covance (Labcorp), and PPD (Thermo Fisher Scientific) provide end-to-end drug development services (SEC filings, 2023)
• •Specialized providers focus on specific therapeutic areas or services such as early-stage research or rare disease trials (FDA Orange Book, 2023)

What drives demand in the industry?

The growth of contract pharmaceutical research services is driven by pharmaceutical companies' need to control R&D costs while maintaining innovation pipelines. Increasingly complex drug development processes and specialized therapeutic areas require specialized expertise that contract providers can offer.

• •Pharmaceutical R&D expenditures in the US reached $91.2 billion in 2022, with significant portions outsourced to contract providers (PhRMA, 2023)
• •The increasing complexity of biologic and cell and gene therapies drives demand for specialized contract research capabilities (FDA, 2023)

Who are the notable companies in the industry?

The competitive landscape includes both large multinational players with broad service portfolios and specialized providers focusing on specific therapeutic areas or research phases. Major firms have expanded through acquisitions to offer comprehensive service offerings from early research through commercialization.

• •IQVIA Holdings Inc. - Provides clinical trial management, data analytics, and research services
• •Labcorp (Covance) - Offers drug development, clinical trials, and laboratory testing services
• •PPD (Thermo Fisher Scientific) - Provides clinical development and laboratory services
• •Parexel International Corporation - Focuses on clinical research and clinical trials

What are the recent trends and outlook?

The industry has seen increased adoption of advanced technologies like artificial intelligence in clinical trial design and data analysis. Companies are also expanding capabilities to support the development of advanced therapies including cell and gene treatments.

• •Adoption of decentralized clinical trial approaches increased by approximately 30% in 2022-2023 (FDA, 2023)
• •Specialized contract services for rare disease therapies have grown significantly, with FDA orphan drug approvals reaching 455 in 2022 (FDA, 2023)

How is the industry regulated?

The industry operates under stringent regulatory requirements including FDA regulations for clinical trials and Good Laboratory Practice (GLP) standards for nonclinical research. Compliance with these regulations is critical for maintaining operations and client relationships.

• •Clinical trials must comply with 21 CFR Part 312 (Investigational New Drug) and Part 812 (Device regulations) (FDA, 2023)
• •Good Laboratory Practice (GLP) standards under 21 CFR Part 58 govern nonclinical laboratory studies (FDA, 2023)
• •Privacy regulations including HIPAA govern the handling of protected health information in clinical trials (HHS, 2023)

Government, statistical and trade sources used for this Claight analysis.

• Bureau of Economic Analysis (BEA) - Industry Economic Accounts 2022 ·
• Pharmaceutical Research and Manufacturers of America (PhRMA) - Industry Profile 2023 ·
• U.S. Food and Drug Administration (FDA) - Orange Book 2023 ·
• U.S. Food and Drug Administration (FDA) - Guidance Documents 2023 ·
• U.S. Department of Health and Human Services (HHS) - HIPAA Regulations 2023